Global Typhoid Fever Vaccines Market Size By Type (Live Attenuated Vaccine, Conjugate Vaccine), By Application (Government Institution, Private Sector), By Region, And Segment Forecasts, 2023 to 2032

The Global Typhoid Fever Vaccines Market was valued at USD 330 million in 2023 and is projected to reach USD 620 million by 2031, growing at a CAGR of 8.2% during the forecast period from 2023 to 2031. The rising incidence of typhoid fever, particularly in low- and middle-income countries, and the increasing focus on preventive healthcare by governments and health organizations are key factors driving market growth. Growing awareness about the availability of effective vaccines and global immunization initiatives are further propelling demand. Technological advancements in vaccine development, such as conjugate vaccines with longer-lasting immunity, are also significantly contributing to market expansion.

Drivers:

1. High Prevalence of Typhoid in Developing Countries:

The burden of typhoid remains high in South Asia, Sub-Saharan Africa, and parts of Latin America. This has prompted extensive vaccination campaigns, which are significantly boosting demand for typhoid vaccines.

2. Government-Led Immunization Initiatives:

Global health organizations, including WHO, GAVI, and UNICEF, are working alongside governments to roll out typhoid conjugate vaccine (TCV) programs, especially in high-risk regions.

3. Advancements in Vaccine Formulation:

The development and approval of typhoid conjugate vaccines (such as Typbar-TCV) that offer longer protection and can be administered to children as young as six months have led to broader immunization coverage.

Restraints:

1. Limited Access and Infrastructure in Remote Areas:

Inadequate cold-chain infrastructure and limited healthcare accessibility in rural regions hinder vaccine distribution and coverage.

2. Vaccine Hesitancy and Misinformation:

Concerns over vaccine safety and a lack of awareness about vaccine benefits in certain regions pose challenges to widespread adoption.

Opportunity:

1. Market Penetration in Underserved Regions:

Expansion into underserved and low-coverage countries in Africa and Southeast Asia presents substantial growth potential for vaccine manufacturers and distributors.

2. Public-Private Partnerships for Expanded Access:

Strategic collaborations between governments, international bodies, and private manufacturers are creating new pathways for affordable vaccine deployment in high-burden regions.

Market by System Type Insights:

Based on vaccine type, the Typhoid Conjugate Vaccines (TCVs) segment dominated the market in 2023, driven by WHO prequalification and widespread adoption in national immunization programs. Their superior immunogenicity, longer duration of protection, and suitability for infants make them the preferred choice over older polysaccharide vaccines.

Market by End-use Insights:

In terms of end-use, the Public Sector emerged as the largest revenue contributor in 2023, fueled by government procurement through immunization programs, often funded by international organizations. Meanwhile, the Private Sector is seeing moderate growth, particularly in urban centers and among travelers seeking preventive care.

Market by Regional Insights:

Asia-Pacific led the global typhoid fever vaccines market in 2023, with countries like India, Pakistan, and Bangladesh exhibiting the highest demand due to endemic presence. Africa is poised to be the fastest-growing region, driven by increased funding and introduction of TCVs into national programs. Latin America and Middle East & Africa are also showing rising demand due to increasing vaccination awareness and support from global health agencies.

Competitive Scenario:

Key players in the Global Typhoid Fever Vaccines Market include Bharat Biotech, Sanofi Pasteur, Biological E Ltd., PaxVax (now Emergent BioSolutions), Bio-Med Pvt Ltd, and PT Bio Farma. These companies are actively investing in R&D, expanding manufacturing capacity, and partnering with global health alliances to broaden vaccine reach.

Key Developments:

In 2023, Bharat Biotech expanded its TCV production facility in India to meet rising global demand.

Sanofi Pasteur strengthened its global supply chain by partnering with UNICEF for typhoid vaccine procurement in low-income countries.

In 2024, Biological E Ltd. launched a new TCV variant with extended shelf life to address distribution challenges in remote regions.

Scope of Work – Global Typhoid Fever Vaccines Market

FAQs:

1) What is the current market size of the Global Typhoid Fever Vaccines Market?

The market was valued at USD 330 million in 2023.

2) What is the major growth driver of the Global Typhoid Fever Vaccines Market?

The primary driver is the increasing incidence of typhoid fever in low- and middle-income countries and strong government-backed immunization programs.

3) Which is the largest region during the forecast period in the Global Typhoid Fever Vaccines Market?

Asia-Pacific holds the largest market share due to the endemic nature of typhoid and widespread vaccine deployment.

4) Which segment accounted for the largest market share in Global Typhoid Fever Vaccines Market?

The Typhoid Conjugate Vaccines (TCVs) segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Typhoid Fever Vaccines Market?

Key players include Bharat Biotech, Sanofi Pasteur, Biological E Ltd., Emergent BioSolutions, and PT Bio Farma.